JPH08807B2 - Novel homoveratryl amine derivative and method for producing the same - Google Patents
Novel homoveratryl amine derivative and method for producing the sameInfo
- Publication number
- JPH08807B2 JPH08807B2 JP13172486A JP13172486A JPH08807B2 JP H08807 B2 JPH08807 B2 JP H08807B2 JP 13172486 A JP13172486 A JP 13172486A JP 13172486 A JP13172486 A JP 13172486A JP H08807 B2 JPH08807 B2 JP H08807B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- isopropyl
- novel
- formula
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical class COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- HNJWKRMESUMDQE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- -1 3,4-dimethoxyphenethyl Chemical group 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000000921 elemental analysis Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical group CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007960 acetonitrile Chemical class 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002213 calciumantagonistic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ZMZSYUSDGRJZNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)acetonitrile Chemical compound C1=CC=C2SC(CC#N)=NC2=C1 ZMZSYUSDGRJZNT-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- UKVQBONVSSLJBB-UHFFFAOYSA-N 2-pyridin-2-ylacetonitrile Chemical compound N#CCC1=CC=CC=N1 UKVQBONVSSLJBB-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WIUKAPGXJDPDAQ-UHFFFAOYSA-N C(C)#N.C(C)(C)Br Chemical class C(C)#N.C(C)(C)Br WIUKAPGXJDPDAQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical class NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、新規なホモベラトリルアミン誘導体及びそ
の製造法に関する。TECHNICAL FIELD The present invention relates to a novel homoveratrylamine derivative and a method for producing the same.
ホモベラトリルアミン系化合物の中には有用な生理作
用を示すものが多く、これらの化合物が医薬品として使
用されていることは周知のとおりである。例えばベラパ
ミルは強いカルシウム拮抗作用を有し、これによつて血
圧降下作用を示すことが知られている(サインエルプロ
ツト及びピーター著「ドラツクス」15巻1978年169〜197
頁参照)。その他のホモベラトリルアミン系化合物とし
ては、心臓血管疾患及び脳循環障害治療剤として有用な
N−メチル−N−ビス(3,4−ジメトキシフエネチル)
アミン誘導体(特開昭59−62553号公報参照)、置換1,5
−ジアミノペンタン誘導体(特開昭58−88343号公報参
照)、ω−シアノ−1,ω−ジフエニルアザアルカン誘導
体(特開昭57−181050号公報参照)などが報告されてい
る。It is well known that many homoveratryl amine compounds exhibit useful physiological actions, and that these compounds are used as pharmaceuticals. For example, verapamil is known to have a strong calcium antagonism and thereby exhibit a blood pressure lowering action (Sin-El-Protto and Peter, "Drax", Vol. 15, 1978, 169-197).
See page). As other homoveratryl amine compounds, N-methyl-N-bis (3,4-dimethoxyphenethyl) useful as a therapeutic agent for cardiovascular diseases and cerebral circulation disorders
Amine derivative (see JP-A-59-62553), substitution 1,5
-Diaminopentane derivatives (see JP-A-58-88343), ω-cyano-1, ω-diphenylazaalkane derivatives (see JP-A-57-181050) and the like have been reported.
本発明者らは、ホモベラトリルアミンの窒素原子上の
置換基として、種々の複素環を有するペンタンニトリル
基を導入した新規なホモベラトリルアミンを合成し、こ
れらの化合物が強いカルシウム拮抗作用を有し、循環器
官系疾患治療薬として有用であることを見い出した。The present inventors have synthesized novel homoveratryl amines in which pentanenitrile groups having various heterocycles are introduced as substituents on the nitrogen atom of homoveratryl amine, and these compounds show strong calcium antagonistic activity. It has been found to be useful as a therapeutic drug for cardiovascular disease.
本発明は、一般式 (式中Hetは置換されてもよいピリジル基、ピロリル
基、フリル基、ベンゾフラニル基、ベンゾキサゾリル
基、ベンゾチエニル基、ベンズイミダゾリル基を示す)
で表わされる新規ホモベラトリルアミン誘導体及びその
酸付加塩である。The present invention has the general formula (In the formula, Het represents an optionally substituted pyridyl group, pyrrolyl group, furyl group, benzofuranyl group, benzoxazolyl group, benzothienyl group, benzimidazolyl group)
A novel homoveratryl amine derivative represented by and an acid addition salt thereof.
本発明のホモベラトリルアミン誘導体(I)及びその
酸付加塩は、カルシウム拮抗作用に基づく優れた血圧降
下作用を有し医薬として有用な化合物である。INDUSTRIAL APPLICABILITY The homoveratrylamine derivative (I) and its acid addition salt of the present invention are compounds having an excellent antihypertensive action based on calcium antagonistic action and useful as a medicine.
式Iの化合物の置換基Hetのためのピリジル基、ピロ
リル基、フリル基、ベンゾフラニル基、ベンゾキサゾリ
ル基、ベンゾチエニル基、ベゾチアゾリル基又はベンズ
イミダゾリル基は、下記の原子又は基を有していてもよ
い。ハロゲン原子例えば塩素原子、臭素原子など、低級
アルキル基例えばメチル基、エチル基、プロピル基、ブ
チル基など、低級アルコキシ基例えばメトキシ基、エト
キシ基、プロポキシ基、ブトキシ基など、ニトロ基、ア
ミノ基、アルキルアミノ基、アミノアルキル基又はアル
キルアミノアルキル基。The pyridyl group, pyrrolyl group, furyl group, benzofuranyl group, benzoxazolyl group, benzothienyl group, bezothiazolyl group or benzimidazolyl group for the substituent Het of the compound of formula I may have the following atoms or groups . Halogen atom such as chlorine atom, bromine atom, etc., lower alkyl group such as methyl group, ethyl group, propyl group, butyl group, etc., lower alkoxy group such as methoxy group, ethoxy group, propoxy group, butoxy group, etc., nitro group, amino group, An alkylamino group, an aminoalkyl group or an alkylaminoalkyl group.
式Iの化合物としては例えば下記のものがあげられ
る。Examples of compounds of formula I include:
2−イソプロピル−2−(2−ピリジル)−5−〔(3,
4−ジメトキシフエネチル)メチルアミノ〕ペンタンニ
トリル(Ia)、 2−イソプロピル−2−(3−ピリジル)−5−〔(3,
4−ジメトキシフエネチル)メチルアミノ〕ペンタニト
リル(1b)、 2−イソプロピル−2−(4−ピリイル)−5−〔(3,
4−ジメトキシフエネチル)メチルアミノ〕ペンタンニ
トリル(1c)、 2−(1−メチル−2−ピロリル)−2−イソプロピル
−5−〔(3,4−ミゼトキシフエネチル)メチルアミ
ノ〕ペンタンニトリル(1d)、 2−(2−フリル)−2−イソプロピル−5−〔(3,4
−ジメトキシフエネチル)メチルアミノ〕ペンタンニト
リル(Ie)、 2−(2−ベンゾフラニル)−2−イソプロピル−5−
〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペン
タンニトリル(If)、 2−(2−ベンゾキサゾリル)−2−イソプロピル−5
−〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペ
ンタンニトリル(Ig)、 2−(2−ベンゾチエニル)−2−イソプロピル−5−
〔(3,4−ジメトキシフエニル)メチルアミノ〕ペンタ
ンニトリル(Ih)、 2−(2−ベンゾチアゾリル)−2−イソプロピル−5
−〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペ
ンタンニトリル(Ii)、 2−(1−メチル−2−ベンズイミダゾリル)−2−イ
ソプロピル−5−〔(3,4−ジメトキシフエネチル)メ
チルアミノ〕ペンタンニトリル(Ij)、 2−(6−メトキシ−2−ベンゾチアゾリル)−2−イ
ソプロピル−5−〔(3,4−ジメトキシフエネチル)メ
チルアミノ〕ペンタンニトリル(Ik)。2-isopropyl-2- (2-pyridyl) -5-[(3,
4-dimethoxyphenethyl) methylamino] pentanenitrile (Ia), 2-isopropyl-2- (3-pyridyl) -5-[(3,
4-dimethoxyphenethyl) methylamino] pentanitrile (1b), 2-isopropyl-2- (4-pyryl) -5-[(3,
4-dimethoxyphenethyl) methylamino] pentanenitrile (1c), 2- (1-methyl-2-pyrrolyl) -2-isopropyl-5-[(3,4-mizetoxyphenethyl) methylamino] pentane Nitrile (1d), 2- (2-furyl) -2-isopropyl-5-[(3,4
-Dimethoxyphenethyl) methylamino] pentanenitrile (Ie), 2- (2-benzofuranyl) -2-isopropyl-5-
[(3,4-Dimethoxyphenethyl) methylamino] pentanenitrile (If), 2- (2-benzoxazolyl) -2-isopropyl-5
-[(3,4-Dimethoxyphenethyl) methylamino] pentanenitrile (Ig), 2- (2-benzothienyl) -2-isopropyl-5
[(3,4-Dimethoxyphenyl) methylamino] pentanenitrile (Ih), 2- (2-benzothiazolyl) -2-isopropyl-5
-[(3,4-Dimethoxyphenethyl) methylamino] pentanenitrile (Ii), 2- (1-methyl-2-benzimidazolyl) -2-isopropyl-5-[(3,4-dimethoxyphenethyl) ) Methylamino] pentanenitrile (Ij), 2- (6-methoxy-2-benzothiazolyl) -2-isopropyl-5-[(3,4-dimethoxyphenethyl) methylamino] pentanenitrile (Ik).
式Iの化合物は一般式 (式中Hetは前記の意味を有する)で表わされるアセト
ニトリル誘導体を、一般式 (式中Xはハロゲン原子を示す)で表わされる化合物と
反応させることにより製造できる。Compounds of formula I have the general formula (Wherein Het has the above meaning), an acetonitrile derivative represented by the general formula It can be produced by reacting with a compound represented by the formula (X represents a halogen atom).
本反応は溶媒中で水素ナトリウム、ナトリウムアミド
等の存在下に行われる。溶媒としては例えばベンゼン、
トルエン、キシレン、ジメチルホルムアミド、ジメチル
スルホキシド等並びにこれらの混合物が用いられる。This reaction is carried out in a solvent in the presence of sodium hydrogen, sodium amide and the like. As the solvent, for example, benzene,
Toluene, xylene, dimethylformamide, dimethylsulfoxide and the like and mixtures thereof are used.
反応温度は60℃ないし溶媒の沸点温度が好ましく、反
応は4〜8時間で完結する。The reaction temperature is preferably 60 ° C. to the boiling point of the solvent, and the reaction is completed in 4 to 8 hours.
式IIの化合物は、例えば一般式 Het−CH2CN IV (式中Hetは前記の意味を有する)で表わされるアセト
ニトリル誘導体をイソプロピルブロミドと反応させるこ
とにより得られる。Compounds of formula II may, for example, the general formula Het-CH 2 CN IV (wherein Het is as defined above) is obtained by reacting isopropyl bromide acetonitrile derivative represented by the.
本反応は溶媒中で苛性アルカリ、苛性アルカリ−トリ
エチルアミン、水素化ナトリウム、ナトリウムアミド等
の存在下に行われる。溶媒としては例えばベンゼン、ト
ルエン、キシレン、ジメチルスルホキイド等並びにこれ
らの混合物が用いられる。This reaction is carried out in a solvent in the presence of caustic, caustic-triethylamine, sodium hydride, sodium amide and the like. As the solvent, for example, benzene, toluene, xylene, dimethyl sulfoxide, etc., and a mixture thereof are used.
反応温度は室温ないし溶媒の沸点温度好ましくは60〜
100℃である。比較的低温で反応させる場合は、反応混
合物を撹拌することが好ましい。反応は通常1〜3時間
で完結する。The reaction temperature is room temperature to the boiling point of the solvent, preferably 60 to
100 ° C. When the reaction is carried out at a relatively low temperature, it is preferable to stir the reaction mixture. The reaction is usually completed in 1 to 3 hours.
式IIの化合物中、α−イソプロピル−3−ピリジルア
セトニトリル、α−イソプロピル−1−メチル−2−ピ
ロリルアセトニトリル、α−イソプロピル−2−フリル
アセトニトリル、α−イソプロピル−2−ベンゾキサゾ
リルアセトニトリル、α−イソプロピル−2−ベンゾチ
エニルアセトニトリル、α−イソプロピル−2−ベンゾ
チアゾリルアセトニトリル、α−イソプロピル−1−メ
チル−2−ベンズイミダゾリルアセトニトリル及びαイ
ソプロピル−6−メトキシ−2−ベンゾチアゾリルアセ
トニトリルは新規化合物である。In the compound of formula II, α-isopropyl-3-pyridylacetonitrile, α-isopropyl-1-methyl-2-pyrrolylacetonitrile, α-isopropyl-2-furylacetonitrile, α-isopropyl-2-benzoxazolylacetonitrile, α-isopropyl-2-benzothienylacetonitrile, α-isopropyl-2-benzothiazolylacetonitrile, α-isopropyl-1-methyl-2-benzimidazolylacetonitrile and α-isopropyl-6-methoxy-2-benzothiazolylacetonitrile Is a novel compound.
式Iの化合物は、一般式 (式中Het及びXは前記の意味を有する)で表わされる
アセトニトリル誘導体をN−メチルホモベラトリルアミ
ンと反応させることによつても得られる。The compound of formula I has the general formula It can also be obtained by reacting an acetonitrile derivative represented by the formula (wherein Het and X have the above meanings) with N-methylhomoveratrylamine.
本反応は無溶媒中で又は反応に関与しない溶媒例えば
アルコール中で行われ、塩基例えばトリエチルアミン、
ピリジン等の存在下に行うことが好ましい。This reaction is carried out without solvent or in a solvent which does not participate in the reaction, for example, alcohol, and a base such as triethylamine,
It is preferable to carry out in the presence of pyridine and the like.
反応温度は60〜120℃が好ましく、反応は通常4〜8
時間で完結する。The reaction temperature is preferably 60 to 120 ° C, and the reaction is usually 4 to 8
Complete in time.
式Vの化合物は式IIのアセトニトリル誘導体をα,γ
−ジハロゲノプロパンと、通常のアルキル化の条件下に
反応させることによつて製造できる。この生成物(V)
は単離精製せずに用いることができる。The compound of formula V is obtained by converting the acetonitrile derivative of formula II into α, γ
It can be prepared by reacting with dihalogenopropane under the conditions of normal alkylation. This product (V)
Can be used without isolation and purification.
反応生成物(I)は常法によつて例えば抽出、カラム
クロマトグラフイ、再結晶等を適宜組み合せて単離精製
できる。The reaction product (I) can be isolated and purified by a conventional method, for example, by appropriately combining extraction, column chromatography, recrystallization and the like.
式Iの化合物は所望により酸付加塩とすることができ
る。そのための酸としては生理的に容認される酸例えば
塩酸、フマル酸、マレイン酸、しゆう酸等が好ましい。The compounds of formula I can optionally be acid addition salts. As the acid therefor, physiologically acceptable acids such as hydrochloric acid, fumaric acid, maleic acid, and citric acid are preferable.
試験例 下記の被験化合物を用いて生成試験を行つた。2−
(2−ベンゾフラニル)−2−イソプロピル−5−
〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペン
タンニトリル(Ifの化合物)、2−(2−ベンゾキサゾ
リル)−2−イソプロピル−5−〔(3,4−ジメトキシ
フエネチル)メチルアミノ〕ペンタンニトリル(Igの化
合物)及び 2−(2−ベンゾチアゾリル)−2−イソプロピル−5
−〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペ
ンタンニトリル(Iiの化合物)。Test Example A production test was conducted using the following test compounds. 2-
(2-Benzofuranyl) -2-isopropyl-5-
[(3,4-Dimethoxyphenethyl) methylamino] pentanenitrile (If compound), 2- (2-benzoxazolyl) -2-isopropyl-5-[(3,4-dimethoxyphenethyl) methylamino] Pentanenitrile (compound of Ig) and 2- (2-benzothiazolyl) -2-isopropyl-5
-[(3,4-Dimethoxyphenethyl) methylamino] pentanenitrile (compound of Ii).
1.カルシウム拮抗作用試験 体重2〜3kgの雌雄ウサギを用い、ペントバルビター
ル・ナトリウムの静脈内投与により麻酔したのち、大腿
動脈放血により致死させ、直ちに胸部大動脈を摘出し
た。摘出した血管はらせん状標本とした。95%酸素及び
5%二酸化炭素の混合ガスを通気し、37℃に保ち、10ml
の栄養液(NaCl147.2、KCl5.4、CaCl22.2、MgCl21.0、N
aHCO314.9、グルコース5.6mM)を入れたマグネス管に摘
出血管標本を1.5gの張力をかけ懸垂した。対照としてKC
l10〜20mM(KCl1M溶液を0.1mlずつ)を累積投与し、段
階的に血管を収縮させ、用量−反応線を得た。次いで被
験薬投与(3用量を使用)10分後に、再びKClの用量−
反応線を得、KCl40mMの投与によつて得られた収縮高を1
00%として、対照の収縮高を50%抑制する被験薬の濃度
をED50値として求めた。その結果を第1表に示す。1. Calcium Antagonism Test Using male and female rabbits having a body weight of 2 to 3 kg, anesthesia was performed by intravenous administration of pentobarbital sodium, and then the femoral artery was exsanguinated to death, and the thoracic aorta was immediately removed. The excised blood vessel was used as a spiral sample. Aerated with a mixed gas of 95% oxygen and 5% carbon dioxide, kept at 37 ° C, and 10 ml.
Nutrient solution (NaCl147.2, KCl5.4, CaCl 2 2.2, MgCl 2 1.0, N
The excised blood vessel sample was suspended in a Magnesian tube containing aHCO 3 14.9 and glucose 5.6 mM) under a tension of 1.5 g. KC as a control
10 to 20 mM (0.1 ml of KCl1M solution) was cumulatively administered, and the blood vessels were gradually contracted to obtain a dose-response line. Then, 10 minutes after the administration of the test drug (using 3 doses), the dose of KCl was again measured-
Obtain the response line and calculate the contraction height obtained by administration of 40 mM KCl as 1
The concentration of the test drug that suppresses the contraction height of the control by 50% was determined as the ED 50 value. The results are shown in Table 1.
2.血圧降下作用試験 体重280〜350gの雄性SHR(収縮期血圧180〜230mmHg)
を約15時間絶食したのち、被験薬を経口投与し、非観血
式血圧測定装置(NARCO,PE−300)を用いて収縮期血圧
の変化を経時的に測定した。その結果を第2表に示す。
なお表中の収縮期血圧は被験薬各用量における最大変化
量を示す。 2. Antihypertensive test Male SHR weighing 280-350g (systolic blood pressure 180-230mmHg)
After fasting for about 15 hours, the test drug was orally administered, and changes in systolic blood pressure were measured over time using a noninvasive blood pressure measuring device (NARCO, PE-300). Table 2 shows the results.
The systolic blood pressure in the table shows the maximum change in each dose of the test drug.
本発明の化合物は、前記の結果より明らかなようにカ
ルシウム拮抗作用及びそれに基づく血圧降下作用を有す
ることが知られた。 As is clear from the above results, the compound of the present invention was known to have a calcium antagonistic action and a hypotensive action based thereon.
参考例1 α−イソプロピル−3−ピリジルアセトニトリルの製造 イソプロピルブロミド20.9g(0.169モル)、水酸化ナ
トリウム13.5g(0.338モル)及びトリエチルアミン0.94
g(0.9×10-3モル)に、窒素気流中60℃に加熱しながら
2−ピリジルアセトニトリル10g(0.085モル)を加え、
80〜90℃で3時間加熱撹拌する。冷後、氷水を加え、エ
ーテル抽出する。エーテル層を水及び飽和食塩水で洗浄
したのち、無水硫酸マグネシウムで乾燥し、溶媒を減圧
留去する。得られる黒褐色油状物を減圧蒸留すると、沸
点77℃/0.2mmHgの帯黄色油状物として、α−イソプロピ
ル−3−ピリジルアセトニトリル9.9g(73.0%)が得ら
れる。Reference Example 1 Production of α-isopropyl-3-pyridylacetonitrile Isopropyl bromide 20.9 g (0.169 mol), sodium hydroxide 13.5 g (0.338 mol) and triethylamine 0.94
2-pyridylacetonitrile 10 g (0.085 mol) was added to g (0.9 x 10 -3 mol) while heating at 60 ° C in a nitrogen stream,
Heat and stir at 80-90 ° C for 3 hours. After cooling, ice water is added and the mixture is extracted with ether. The ether layer is washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The resulting black-brown oily substance is distilled under reduced pressure to obtain 9.9 g (73.0%) of α-isopropyl-3-pyridylacetonitrile as a yellowish oily substance having a boiling point of 77 ° C / 0.2 mmHg.
元素分析値:C10H12N2として C H N 理論値(%) 74.97 7.55 17.48 実験値(%) 74.94 7.56 17.46 同様にして既知化合物であるα−イソプロピル−2−
ピリジルアセトニトリル、α−イソプロピル−4−ピリ
ジルアセトニトリル及びα−イソピロピル−2−ベンゾ
フラニルアセトニトリルを得た。Elemental analysis value: C H N theoretical value (%) as C 10 H 12 N 2 74.97 7.55 17.48 Experimental value (%) 74.94 7.56 17.46 Similarly, α-isopropyl-2- which is a known compound.
Pyridylacetonitrile, α-isopropyl-4-pyridylacetonitrile and α-isopyropyr-2-benzofuranylacetonitrile were obtained.
参考例2 α−イソプロイル−2−ベンゾチアゾリルアセトニトリ
ルの製造 50%アトリウムヒドリド1.25g(2.6×10-2モル)に無
水トルエン10mlを加え、室温撹拌下に無水トルエン−ジ
メチルスルホキシド(2:1)の混合溶媒30mlに溶解した
2−ベンゾチアゾリルアセトニトリル3.48g(2×10-2
モル)を摘加し、窒素気流中2時間撹拌する。次いでイ
ソプロピルブロミド3.69g(3×10-2モル)を加え、90
〜100℃で2時間加熱撹拌する。冷後、反応混合物に氷
水を加え、エーテル抽出する。エーテル層を水及び飽和
食塩水で洗浄したのち、無水硫酸マグネシウムで乾燥
し、溶媒を減圧留去する。得られる黄赤色油状物をシリ
カゲルカラムクロマトグラフイに付し、酢酸エチル−n
−ヘキサン(1:7)の溶出部より黄色結晶性残査を得
る。これをn−ヘキサンから再結晶すると、融点56〜57
℃の帯黄色針状晶として、α−イソプロピル−2−ベン
ゾチアゾリルアセトニトリル1.66g(47.7%)が得られ
る。Reference Example 2 Production of α-isoproyl-2-benzothiazolylacetonitrile 10 ml of anhydrous toluene was added to 1.25 g (2.6 × 10 -2 mol) of 50% atrium hydride, and anhydrous toluene-dimethylsulfoxide (2: 1 was added under stirring at room temperature. ) 2. Benzothiazolyl acetonitrile 3.48 g (2 x 10 -2
Mol) and stirred in a nitrogen stream for 2 hours. Then add 3.69 g (3 × 10 -2 mol) of isopropyl bromide, and add 90
Heat and stir at ~ 100 ° C for 2 hours. After cooling, ice water is added to the reaction mixture and the mixture is extracted with ether. The ether layer is washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The obtained yellow-red oily substance was subjected to silica gel column chromatography to obtain ethyl acetate-n.
-A yellow crystalline residue is obtained from the eluate of hexane (1: 7). When recrystallized from n-hexane, the melting point is 56-57.
1.66 g (47.7%) of α-isopropyl-2-benzothiazolylacetonitrile are obtained as yellowish needle crystals at ℃.
元素分析値:C12H12N2Sとして C H N 理論値(%) 66.63 5.59 12.95 実験値(%) 66.89 5.62 13.06 同様にして下記の化合物が得られる。Elemental analysis value: C H N theoretical value (%) 66.63 5.59 12.95 experimental value (%) 66.89 5.62 13.06 as C 12 H 12 N 2 S The following compounds are obtained in the same manner.
α−イソプロピル−1−メチル−2−ピロリルアセトニ
トリル 収率:32.6% 無色油状物、▲n24 D▼:1.4973 元素分析値:C10H14N2・1/10H2Oとして C H N 理論値(%) 73.22 8.73 17.07 実験値(%) 73.28 8.86 16.98 α−イソプロピル−2−フリルアセトニトリル 収率:31.3% 帯黄色油状物、沸点:95℃/20mmHg ▲n24 D▼:1.4622 元素分析値:C9H11NO・1/10H2Oとして C H N 理論値(%) 71.73 7.94 9.30 実験値(%) 71.59 7.45 9.20 α−イソプロピル−2−ベンゾキサゾリルアセトニトリ
ル 収率:56.9% 帯黄色飴状物、▲n24 D▼:1.5335 元素分析値:C12H12N2Oとして C H N 理論値(%) 71.98 6.04 13.99 実験値(%) 71.78 6.09 13.97 α−イソプロピル−2−ベンゾチエニルアセトニトリル 収率:49.0% 無色微細針状晶、融点:69〜71℃ 元素分析値:C13H13NSとして C H N 理論値(%) 72.52 6.09 6.51 実験値(%) 72.34 6.10 6.43 α−イソプロピル−1−メチル−2−ベンズイミダゾリ
ルアセトニトリル 収率:56.7% 無色針状晶、融点105〜106℃ 元素分析値:C13H15N3として C H N 理論値(%) 73.21 7.09 19.70 実験値(%) 73.40 7.22 19.81 α−イソプロピル−6−メトキシ−2−ベンゾチアゾリ
ルアセトニトリル 収率:53.3% 帯黄色油状物、▲n24 D▼:1.5811 元素分析値:C13H14N2OSとして C H N 理論値(%) 63.39 5.73 11.37 実験値(%) 63.13 5.73 11.30 実施例1 2−イソプロピル−2−(2−フリル)−5−〔(3,4
−ジメトキシフエネチル)メチルアミノ〕ペンタンニト
リルの製造 α−イソプロピル−2−フリルアセトニトリル600mg
(4×10-3モル)、N−(3−クロロプロピル)−N−
メチルホモベラトリルアミン11g(4×10-3モル)及び
ナトリウムアミド362mg(9.3×10-3モル)に無水トルエ
ン15mlを加え窒素気流中に4時間加熱還流する。α-isopropyl-1-methyl-2-pyrrolylacetonitrile Yield: 32.6% Colorless oil, ▲ n 24 D ▼: 1.4973 Elemental analysis: C 10 H 14 N 2 · 1 / 10H 2 O CHN theory Value (%) 73.22 8.73 17.07 Experimental value (%) 73.28 8.86 16.98 α-Isopropyl-2-furylacetonitrile Yield: 31.3% Yellowish oil, boiling point: 95 ° C / 20mmHg ▲ n 24 D ▼: 1.4622 Elemental analysis: As C 9 H 11 NO ・ 1 / 10H 2 O CH N theoretical value (%) 71.73 7.94 9.30 experimental value (%) 71.59 7.45 9.20 α-isopropyl-2-benzoxazolylacetonitrile yield: 56.9% yellowish candy Substance, ▲ n 24 D ▼: 1.5335 Elemental analysis value: C 12 H 12 N 2 O CH N theoretical value (%) 71.98 6.04 13.99 Experimental value (%) 71.78 6.09 13.97 α-isopropyl-2-benzothienylacetonitrile yield: 49.0% colorless fine needle crystals, mp: 69-71 ° C. elemental analysis: C 13 H 13 NS as C H N Logical value (%) 72.52 6.09 6.51 Found (%) 72.34 6.10 6.43 alpha-isopropyl-1-methyl-2-benzimidazolyl acetonitrile. Yield: 56.7% colorless needles, mp 105-106 ° C. Elemental analysis: C 13 CH 3 as H 15 N 3 theoretical value (%) 73.21 7.09 19.70 experimental value (%) 73.40 7.22 19.81 α-isopropyl-6-methoxy-2-benzothiazolylacetonitrile yield: 53.3% yellowish oil, ▲ n 24 D ▼: 1.5811 Elemental analysis value: C 13 H 14 N 2 OS C H N theoretical value (%) 63.39 5.73 11.37 Experimental value (%) 63.13 5.73 11.30 Example 1 2-isopropyl-2- (2-furyl) ) -5-[(3,4
Preparation of -dimethoxyphenethyl) methylamino] pentanenitrile α-isopropyl-2-furylacetonitrile 600 mg
(4 × 10 −3 mol), N- (3-chloropropyl) -N-
To 11 g (4 × 10 −3 mol) of methyl homoveratrylamine and 362 mg (9.3 × 10 −3 mol) of sodium amide were added 15 ml of anhydrous toluene, and the mixture was heated under reflux for 4 hours in a nitrogen stream.
冷後、反応混合物に氷水を加え、エーテル抽出する。
エーテル層を水及び飽和食塩水で洗浄したのち、無水硫
酸マグネシウムで乾燥し、溶媒を減圧留去する。得られ
る赤褐色油状物をシリカゲルカラムクロマトグラフイに
付し、クロロホルム−メタノール(98:2)の溶出部より
帯黄色油状物458mgを得る。この油状物をエタノール中
しゆう酸塩を形成させエタノール−エーテルから再結晶
すると、融点139〜140℃の無色粉末として、2−イソプ
ロピル−2−(2−フリル)−5−〔(3,4−ジメトキ
シフエネチル)メチルアミノ〕ペンタンニトリル(しゆ
う酸塩)508mg(26.8%)が得られる。After cooling, ice water is added to the reaction mixture and the mixture is extracted with ether.
The ether layer is washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The obtained reddish brown oily matter was subjected to silica gel column chromatography to obtain 458 mg of a yellowish oily matter from the elution part of chloroform-methanol (98: 2). When this oily substance was recrystallized from ethanol-ether by forming a oxalate salt in ethanol, 2-isopropyl-2- (2-furyl) -5-[(3,4) was obtained as a colorless powder having a melting point of 139-140 ° C. 508 mg (26.8%) of dimethoxyphenethyl) methylamino] pentanenitrile (oxalate) are obtained.
元素分析値:C23H32N2O3・(CO2H)2として C H N 理論値(%) 63.28 7.22 5.90 実験値(%) 63.32 7.21 5.87 同様にして下記化合物が得られる。Elemental analysis value: C 23 H 32 N 2 O 3 · (CO 2 H) 2 C H N theoretical value (%) 63.28 7.22 5.90 Experimental value (%) 63.32 7.21 5.87 The following compounds are obtained in the same manner.
2−イソプロピル−2−(4−ピリジル)−5−〔(3,
4−ジメトキシフエネチル)メチルアミノ〕ペンタンニ
トリル(しゆう酸塩) 収率:19.0% 無色粒状晶、融点:154〜155℃(エタノール−酢酸エチ
ル) 元素分析値:C24H33N3O2・(CO2H)2として C H N 理論値(%) 64.31 7.26 8.65 実験値(%) 64.05 7.23 8.59 2−(1−メチル−2−ベンズイミダゾリル)−2−イ
ソプロピル−5−〔(3,4−ジメトキシフエネチル)メ
チルアミノ〕ペンタンニトリル(しゆう酸塩) 収率:49.5% 無色微細針状晶、融点:134〜135℃(メタノール−エー
テル) 元素分析値:C27H36N4O2・(CO2H)2・H2Oとして C H N 理論値(%) 62.57 7.24 10.06 実験値(%) 62.54 7.08 10.05 実施例2 2−イソプロピル−2−(2−ベンゾチアゾリル)−5
−〔(3,4−ジメトキシフエネチル)メチルアミノ〕ペ
ンタンニトリルの製造 ナトリウムアミド0.42g(10.8×10-3モル)に無水ト
ルエン−ジメチルスルホキシド(1:1)の混合溶媒10ml
を加え室温撹拌下にα−イソプロピル−2−ベンゾチア
ゾリルアセトニトリル1.44g(8.3×10-3モル)を加え、
50〜60℃で1時間加熱撹拌する。次いで同温度で1−ブ
ロモ−3−クロロプロパン2.6g(16.5×10-3モル)を加
え、1時間撹拌する。冷後、氷水にあけエーテルで抽出
する。エーテル層を水及び飽和食塩水で洗浄したのち、
無水硫酸マグネシウムで乾燥し、溶媒及び過剰の1−ブ
ロモ−3−クロロプロパンを減圧留去すると、黄色油状
物として、粗α−(3−クロロプロピル)−α−イソプ
ロピル−2−ベンゾチアゾリルアセトニトリル2.1gが得
られる。この粗生成物を、シリカゲルカラムクロマトグ
ラフイ〔酢酸エチル−n−ヘキサン(1:7)〕により精
製すると、▲n24 D▼1.5702の帯黄色油状物となる。2-isopropyl-2- (4-pyridyl) -5-[(3,
4-dimethoxyphenethyl) methylamino] pentanenitrile (silic acid salt) Yield: 19.0% colorless granular crystals, melting point: 154-155 ° C (ethanol-ethyl acetate) Elemental analysis value: C 24 H 33 N 3 O 2・ (CO 2 H) 2 CH N theoretical value (%) 64.31 7.26 8.65 experimental value (%) 64.05 7.23 8.59 2- (1-methyl-2-benzimidazolyl) -2-isopropyl-5 [(3 , 4-Dimethoxyphenethyl) methylamino] pentanenitrile (silic acid salt) Yield: 49.5% Colorless fine needle crystals, melting point: 134-135 ° C (methanol-ether) Elemental analysis value: C 27 H 36 N 4 O 2 · (CO 2 H) 2 · H 2 O CHN theoretical value (%) 62.57 7.24 10.06 Experimental value (%) 62.54 7.08 10.05 Example 2 2-isopropyl-2- (2-benzothiazolyl) -5
Preparation of-[(3,4-dimethoxyphenethyl) methylamino] pentanenitrile 10 ml of a mixed solvent of 0.42 g (10.8 x 10 -3 mol) of sodium amide and anhydrous toluene-dimethyl sulfoxide (1: 1)
And α-isopropyl-2-benzothiazolylacetonitrile 1.44 g (8.3 × 10 -3 mol) were added with stirring at room temperature,
Heat and stir at 50-60 ° C for 1 hour. Then, 2.6 g (16.5 × 10 −3 mol) of 1-bromo-3-chloropropane was added at the same temperature, and the mixture was stirred for 1 hour. After cooling, it is poured into ice water and extracted with ether. After washing the ether layer with water and saturated saline,
After drying over anhydrous magnesium sulfate, the solvent and excess 1-bromo-3-chloropropane were distilled off under reduced pressure to give a crude oily α- (3-chloropropyl) -α-isopropyl-2-benzothiazolylacetonitrile. 2.1 g are obtained. The crude product is purified by silica gel column chromatography [ethyl acetate-n-hexane (1: 7)] to give a yellowish oil of (n 24 D) 1.5702.
得られた粗α−(3−クロロプロピル)−α−イソプ
ロピル−2−ベンゾチアゾリルアセトニトリル1.75gに
N−メチルホモベラトリルアミン2.33g(12×10-3モ
ル)及びトリエチルアミン4mlを加え、8時間加熱還流
する。冷後、氷水を加え、エーテルで抽出する。エーテ
ル層を水及び飽和食塩水で洗浄したのち、無水硫酸マグ
ネシウムで乾燥し、溶媒を減圧留去する。得られる黄色
油状物をシリカゲルカラムクロマトグラフイに付し、ク
ロロホルム−メタノール(98:2)の溶出部より帯黄色油
状物2.35gを得る。この油状物をメタノール中でしゆう
酸塩を形成させ、エタノールから再結晶すると、融点17
4〜175℃の無色針状晶として、2−イソプロピル−2−
(2−ベンゾチアゾリル)−5−〔(3,4−ジメトキシ
フエネチル)アミノ〕ペンタンニトリル(しゆう酸塩)
2.25g(60.4%)が得られる。To 1.75 g of the obtained crude α- (3-chloropropyl) -α-isopropyl-2-benzothiazolylacetonitrile, 2.33 g (12 × 10 −3 mol) of N-methylhomoveratrylamine and 4 ml of triethylamine were added, Heat at reflux for 8 hours. After cooling, add ice water and extract with ether. The ether layer is washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The resulting yellow oil is subjected to silica gel column chromatography, and 2.35 g of a yellowish oil is obtained from the elution part of chloroform-methanol (98: 2). The oil was formed into oxalate salt in methanol and recrystallized from ethanol to give a melting point of 17
As colorless needles at 4-175 ° C, 2-isopropyl-2-
(2-Benzothiazolyl) -5-[(3,4-dimethoxyphenethyl) amino] pentanenitrile (silic acid salt)
2.25 g (60.4%) are obtained.
元素分析値:C26H33N2O2S・(CO2H)2として C H N 理論値(%) 62.09 6.51 7.76 実験値(%) 61.92 6.65 7.68 同様にして第3表に示す化合物が得られる。表中の元
素分析値欄の上段は理論値、下段は実験値である。Elemental analysis value: C 26 H 33 N 2 O 2 S · (CO 2 H) 2 C H N theoretical value (%) 62.09 6.51 7.76 Experimental value (%) 61.92 6.65 7.68 Similarly, the compounds shown in Table 3 were obtained. can get. The upper column of the elemental analysis value column in the table is the theoretical value, and the lower column is the experimental value.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 C07D 307/54 307/79 333/60 // A61K 31/34 31/38 31/40 ABN 31/415 31/42 31/425 31/44 ADD (72)発明者 成田 仙一 埼玉県浦和市領家6−14−7 (56)参考文献 特開 昭61−289090(JP,A) 特開 昭61−106578(JP,A) 特公 昭49−46629(JP,B1)Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI Technical display area C07D 307/54 307/79 333/60 // A61K 31/34 31/38 31/40 ABN 31/415 31 / 42 31/425 31/44 ADD (72) Inventor Senichi Narita 6-14-7 Ryoke, Urawa-shi, Saitama (56) Reference JP-A 61-289090 (JP, A) JP-A 61-106578 (JP, A) Japanese Patent Publication Sho 49-46629 (JP, B1)
Claims (3)
基、フリル基、ベンゾフラニル基、ベンゾキサゾリル
基、ベンゾチエニル基又はベンズイミダゾリル基を示
す)で表される新規ホモベラトリルアミン誘導体及びそ
の酸付加塩。1. A general formula (Wherein Het represents an optionally substituted pyridyl group, a pyrrolyl group, a furyl group, a benzofuranyl group, a benzoxazolyl group, a benzothienyl group or a benzimidazolyl group), and a novel homoveratryl amine derivative and an acid addition salt thereof. .
基、フリル基、ベンゾフラニル基、ベンゾキサゾリル
基、ベンゾチエニル基又はベンズイミダゾリル基を示
す)で表される化合物を、一般式 (式中Xはハロゲン原子を示す)で表される化合物と反
応させることを特徴とする一般式 (式中Xは前記の意味を有する)で表される新規ホモベ
ラトリルアミン誘導体の製造法。2. General formula (Wherein Het represents an optionally substituted pyridyl group, pyrrolyl group, furyl group, benzofuranyl group, benzoxazolyl group, benzothienyl group or benzimidazolyl group), a compound represented by the general formula A general formula characterized by reacting with a compound represented by the formula (wherein X represents a halogen atom) A process for producing a novel homoveratryl amine derivative represented by the formula (wherein X has the above meaning).
基、フリル基、ベンゾフラニル基、ベンゾキサゾリル
基、ベンゾチエニル基又はベンズイミダゾリル基を、X
はハロゲン原子を示す)で表される化合物を、N−メチ
ルホモベラトリルアミンと反応させることを特徴とする
一般式 (式中Xは前記の意味を有する)で表される新規ホモベ
ラトリルアミン誘導体の製造法。3. General formula (Wherein Het represents an optionally substituted pyridyl group, pyrrolyl group, furyl group, benzofuranyl group, benzoxazolyl group, benzothienyl group or benzimidazolyl group, X
Represents a halogen atom) and is reacted with N-methyl homoveratryl amine. A process for producing a novel homoveratryl amine derivative represented by the formula (wherein X has the above meaning).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13172486A JPH08807B2 (en) | 1986-06-09 | 1986-06-09 | Novel homoveratryl amine derivative and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13172486A JPH08807B2 (en) | 1986-06-09 | 1986-06-09 | Novel homoveratryl amine derivative and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62289560A JPS62289560A (en) | 1987-12-16 |
| JPH08807B2 true JPH08807B2 (en) | 1996-01-10 |
Family
ID=15064716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13172486A Expired - Fee Related JPH08807B2 (en) | 1986-06-09 | 1986-06-09 | Novel homoveratryl amine derivative and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08807B2 (en) |
-
1986
- 1986-06-09 JP JP13172486A patent/JPH08807B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62289560A (en) | 1987-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0254322B1 (en) | Benzimidazole derivatives | |
| CN100508975C (en) | Use of pyrazolopyridine compound | |
| JPS63165380A (en) | Novel compound, its procuction and pharmaceutical composition containing the same | |
| JPH06509820A (en) | Selective phosphodiesterase ■Trisubstituted phenyl derivatives as inhibitors | |
| JPH0229671B2 (en) | ||
| JPH01265100A (en) | 2-substituted adenosine derivatives | |
| JPH0367071B2 (en) | ||
| JP2000063363A (en) | New triazole derivative | |
| US4243666A (en) | 4-Amino-2-piperidino-quinazolines | |
| JPS5955878A (en) | Novel phenylpiperazine derivative | |
| US5635511A (en) | Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds. | |
| JPS6342622B2 (en) | ||
| WO1997026242A1 (en) | 3-(bis-substituted-phenylmethylene)oxindole derivatives | |
| JPH0433793B2 (en) | ||
| EP0381235A2 (en) | Pyrrolidine compound and pharmaceutical use | |
| JPH0377867A (en) | New oxazolopiperizine derivative | |
| JP2834506B2 (en) | Novel thienyloxy-alkylamine derivatives, their preparation and medicaments containing this compound | |
| JPH0358973A (en) | N,n'-bis(alkoxyalkyl)-pyridine-2,4- dicarboxylic acid diamides | |
| US4912135A (en) | Amide compounds | |
| GB2171997A (en) | 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives | |
| JPH0339073B2 (en) | ||
| JPH08807B2 (en) | Novel homoveratryl amine derivative and method for producing the same | |
| JPS61158980A (en) | 8α-acylaminoergolines, their production methods and pharmaceutical compositions | |
| KR880001715B1 (en) | Process for preparing 1-furyl-3,4-dihydro-isoquinolines | |
| HU194213B (en) | Process for production of 3-alkoxi-2-n-pirrolidin-n-piridil-n-furil /or n-tienil/-methil-prophil amins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |